The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital

Gynecologic Oncology

Volumn 92, Issue 2, 2004, Pages 648-652

  Dinh, Tri A ^a   Oliva, Esther A ^a   Fuller Jr , Arlan F ^a   Lee, Hang ^a   Goodman, Annekathryn ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cytoreduction; Leiomyosarcoma; Surgery; Survival

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; ANASTROZOLE; ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; NAVELBINE; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; TAMOXIFEN; TRABECTEDIN;

ADULT; ASSOCIATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GENERAL HOSPITAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MEDICAL PRACTICE; MEDICAL RECORD; MITOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; UTERUS CARCINOMA;

EID: 0842332132     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.10.044     Document Type: Article

References (19)

1. Echt G., Jepson J., Steel J., Langholz B., Luxton G., Hernandez W.et al. Treatment of uterine sarcomas. Cancer. 66(1):1990;35-39.
2. Gadducci A., Landoni F., Sartori E., Zola P., Maggino T., Lissoni A.et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol. Oncol. 62(1):1996;25-32.
3. Salazar O.M., Bonfiglio T.A., Patten S.F., Keller B.E., Feldstein M., Dunne M.E.et al. Uterine sarcomas: natural history, treatment and prognosis. Cancer. 42(3):1978;1152-1160.
4. Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasman W.T., Currie J.L.et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 71(4 Suppl.):1993;1702-1709.
5. Sutton G., Blessing J.A., Malfetano J.H. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 62(2):1996;226-229.
6. Kempson R.L., Bari W. Uterine sarcomas. Classification, diagnosis, and prognosis. Hum. Pathol. 1(3):1970;331-349.
7. Bell S.W., Kempson R.L., Hendrickson M.R. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am. J. Surg. Pathol. 18(6):1994;535-558.
8. Vardi J.R., Tovell H.M. Leiomyosarcoma of the uterus: clinicopathologic study. Obstet. Gynecol. 56(4):1980;428-434.
9. Hannigan E.V., Gomez L.G. Uterine leiomyosarcoma. Am. J. Obstet. Gynecol. 134(5):1979;557-564.
10. Goff B.A., Rice L.W., Fleischhacker D., Muntz H.G., Falkenberry S.S., Nikrui N.et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol. Oncol. 50(1):1993;105-109.
11. Berchuck A., Rubin S.C., Hoskins W.J., Saigo P.E., Pierce V.K., Lewis J.L. Treatment of uterine leiomyosarcoma. Obstet. Gynecol. 71(6 Pt 1):1988;845-850.
12. Lang H., Nussbaum K.T., Kaudel P., Fruhauf N., Flemming P., Raab R. Hepatic metastases from leiomyosarcoma: a single-center experience with 34 liver resections during a 15-year period. Ann. Surg. 231(4):2000;500-505.
13. Borden E.C., Amato D.A., Rosenbaum C., Enterline H.T., Shiraki M.J., Creech R.H.et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J. Clin. Oncol. 5(6):1987;840-850.
14. Thigpen T., Blessing J.A., Yordan E., Valea F., Vaccarello L. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 63(1):1996;120-122.
15. Sutton G., Blessing J.A., Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 74(3):1999;346-349.
16. Smith H.O., Blessing J.A., Vaccarello L. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 84(1):2002;140-144.
17. Gallup D.G., Blessing J.A., Andersen W., Morgan M.A. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 89(1):2003;48-51.
18. Hensley M.L., Maki R., Venkatraman E., Geller G., Lovegren M., Aghajanian C.et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J. Clin. Oncol. 20(12):2002;2824-2831.
19. Dinh T.V., Woodruff J.D. Leiomyosarcoma of the uterus. Am. J. Obstet. Gynecol. 144(7):1982;817-823.